Canadian drug developer Medicago says a combination of its experimental COVID-19 vaccine and GlaxoSmithKline’s vaccine booster produced an antibody response in a Phase 1 clinical trial.
Medicago reports promising but preliminary results of possible COVID-19 vaccine
